Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe

Varicella is a mild and self-limited illness in children, but can result in significant healthcare resource utilization (HCRU). To quantify/contrast varicella-associated HCRU in five middle-income countries (Hungary, Poland, Argentina, Mexico, and Peru) where universal varicella vaccination was unim...

Full description

Bibliographic Details
Main Authors: Lara J. Wolfson, Maria Esther Castillo, Norberto Giglio, Zsofia Meszner, Zsuzsanna Molnar, Mirella Vazquez, Jacek Wysocki, Alexandra Altland, Barbara J. Kuter, Jenaya Rickard, Emmanouil Rampakakis
Format: Article
Language:English
Published: Taylor & Francis Group 2019-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2018.1559687
_version_ 1827809725492756480
author Lara J. Wolfson
Maria Esther Castillo
Norberto Giglio
Zsofia Meszner
Zsuzsanna Molnar
Mirella Vazquez
Jacek Wysocki
Alexandra Altland
Barbara J. Kuter
Jenaya Rickard
Emmanouil Rampakakis
author_facet Lara J. Wolfson
Maria Esther Castillo
Norberto Giglio
Zsofia Meszner
Zsuzsanna Molnar
Mirella Vazquez
Jacek Wysocki
Alexandra Altland
Barbara J. Kuter
Jenaya Rickard
Emmanouil Rampakakis
author_sort Lara J. Wolfson
collection DOAJ
description Varicella is a mild and self-limited illness in children, but can result in significant healthcare resource utilization (HCRU). To quantify/contrast varicella-associated HCRU in five middle-income countries (Hungary, Poland, Argentina, Mexico, and Peru) where universal varicella vaccination was unimplemented, charts were retrospectively reviewed among 1–14 year-olds. Data were obtained on management of primary varicella between 2009–2016, including outpatient/inpatient visits, allied healthcare contacts, tests/procedures, and medications. These results are contrasted across countries, and a regression model is fit to extrapolated country-level costs as a function of gross domestic product (GDP). A total of 401 outpatients and 386 inpatients were included. Significant differences between countries were observed in the number of skin lesions among outpatients, ranging from 5.3% to 25.4% of patients with ≥250 lesions. Among inpatients, results were less variable. Average ambulatory medical visits ranged from 1.1 to 2.2. Average hospital stay ranged from 3.6 to 6.8 days. Use of tests/procedures was infrequent in outpatients, except in Argentina (13.3%); among inpatients, a test/procedure was ordered for 81.3% of patients, without regional variation. Prescription medications were administered in 44.4% of outpatients (range 9.3%–80.0%), and in 86% of inpatients (range 70.4%–94.9%). Total estimated spending on varicella treatment in the absence of vaccination was predicted from income levels (GDP) with an exponential function (R2 = 0.89). This study demonstrates that substantial HCRU is associated with varicella resulting in significant public health burden that could be alleviated through the use of varicella vaccination. Differences observed between countries possibly reflect treatment guidelines, healthcare resource availabilities and physician practices.
first_indexed 2024-03-11T22:44:57Z
format Article
id doaj.art-82b2e376f742422f8b4dac0c583a42fc
institution Directory Open Access Journal
issn 2164-5515
2164-554X
language English
last_indexed 2024-03-11T22:44:57Z
publishDate 2019-04-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj.art-82b2e376f742422f8b4dac0c583a42fc2023-09-22T08:38:25ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-04-0115493294110.1080/21645515.2018.15596871559687Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & EuropeLara J. Wolfson0Maria Esther Castillo1Norberto Giglio2Zsofia Meszner3Zsuzsanna Molnar4Mirella Vazquez5Jacek Wysocki6Alexandra Altland7Barbara J. Kuter8Jenaya Rickard9Emmanouil Rampakakis10Merck & Co., IncInstituto Nacional de Salud del Niño (INSN)Hospital de Niños Ricardo GutiérrezSt. László Hospital for Infectious DiseasesNational Center for EpidemiologyInstituto Nacional de PediatríaPoznan University of Medical SciencesMerck & Co., IncMerck & Co., IncJSS Medical ResearchJSS Medical ResearchVaricella is a mild and self-limited illness in children, but can result in significant healthcare resource utilization (HCRU). To quantify/contrast varicella-associated HCRU in five middle-income countries (Hungary, Poland, Argentina, Mexico, and Peru) where universal varicella vaccination was unimplemented, charts were retrospectively reviewed among 1–14 year-olds. Data were obtained on management of primary varicella between 2009–2016, including outpatient/inpatient visits, allied healthcare contacts, tests/procedures, and medications. These results are contrasted across countries, and a regression model is fit to extrapolated country-level costs as a function of gross domestic product (GDP). A total of 401 outpatients and 386 inpatients were included. Significant differences between countries were observed in the number of skin lesions among outpatients, ranging from 5.3% to 25.4% of patients with ≥250 lesions. Among inpatients, results were less variable. Average ambulatory medical visits ranged from 1.1 to 2.2. Average hospital stay ranged from 3.6 to 6.8 days. Use of tests/procedures was infrequent in outpatients, except in Argentina (13.3%); among inpatients, a test/procedure was ordered for 81.3% of patients, without regional variation. Prescription medications were administered in 44.4% of outpatients (range 9.3%–80.0%), and in 86% of inpatients (range 70.4%–94.9%). Total estimated spending on varicella treatment in the absence of vaccination was predicted from income levels (GDP) with an exponential function (R2 = 0.89). This study demonstrates that substantial HCRU is associated with varicella resulting in significant public health burden that could be alleviated through the use of varicella vaccination. Differences observed between countries possibly reflect treatment guidelines, healthcare resource availabilities and physician practices.http://dx.doi.org/10.1080/21645515.2018.1559687varicellapediatricshealthcare resource utilization (hcru)costsmulti-country
spellingShingle Lara J. Wolfson
Maria Esther Castillo
Norberto Giglio
Zsofia Meszner
Zsuzsanna Molnar
Mirella Vazquez
Jacek Wysocki
Alexandra Altland
Barbara J. Kuter
Jenaya Rickard
Emmanouil Rampakakis
Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe
Human Vaccines & Immunotherapeutics
varicella
pediatrics
healthcare resource utilization (hcru)
costs
multi-country
title Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe
title_full Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe
title_fullStr Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe
title_full_unstemmed Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe
title_short Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe
title_sort varicella healthcare resource utilization in middle income countries a pooled analysis of the multi country marvel study in latin america europe
topic varicella
pediatrics
healthcare resource utilization (hcru)
costs
multi-country
url http://dx.doi.org/10.1080/21645515.2018.1559687
work_keys_str_mv AT larajwolfson varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT mariaesthercastillo varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT norbertogiglio varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT zsofiameszner varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT zsuzsannamolnar varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT mirellavazquez varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT jacekwysocki varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT alexandraaltland varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT barbarajkuter varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT jenayarickard varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope
AT emmanouilrampakakis varicellahealthcareresourceutilizationinmiddleincomecountriesapooledanalysisofthemulticountrymarvelstudyinlatinamericaeurope